Q3 2024 Plus Therapeutics Inc Earnings Call Transcript
Key Points
- Plus Therapeutics Inc (PSTV) has made significant progress in its leptomeningeal metastases program, with the FDA agreeing to proceed under a multiple dose escalation protocol.
- The company reported favorable safety and tolerability results for doses of RNL up to 44 millicuries, with no dose-limiting toxicities observed.
- Plus Therapeutics Inc (PSTV) has secured substantial grant funding, including a $3 million award from the US Department of Defense and ongoing support from the NIH.
- The company is expanding its manufacturing capabilities, ensuring a reliable supply of RNL with a new GMP manufacturing partnership.
- Plus Therapeutics Inc (PSTV) is on track to commercially reintroduce its C Inside diagnostic test in early 2025, with plans for expanded market access and reimbursement.
- The cash and investment balance decreased to $4.8 million as of September 2024, down from $8.6 million in December 2023.
- The company reported a net loss of $9.1 million year-to-date 2024, indicating ongoing financial challenges.
- There is uncertainty regarding the timeline for obtaining necessary regulatory approvals and reimbursement codes for the C Inside diagnostic test.
- The therapeutic ratio for the RNL trials is still being evaluated, with potential safety concerns as the dose escalates.
- The company faces challenges in securing additional grant funding, with potential changes in government affecting future opportunities.
Good afternoon. Ladies and gentlemen, welcome to the Plus Therapeutics third quarter, 2024 results conference call. Before we begin, we want to advise you that over the course of the call, including any question and answer session. Forward-looking statements will be made regarding events, trends, business prospects and financial performance which may affect plus therapeutics', future operating results and financial position. All such statements are subject to risks and uncertainties including the risks and uncertainties described under the risk factors section included in Plus therapeutics', annual report on form 10-K and quarterly reports on form 10-Q filed with the Securities and Exchange Commission from time to time. Plus therapeutics advises you to review these risk factors in considering such statements. Plus therapeutics assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
It is now my pleasure to turn the floor over to Dr Mark Hedrick Plus Therapeutics, President and Chief Executive Officer, sir
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
